Carefully selected cases are presented by fellows from around the globe. Retina cases you would not believe! Real-world treatment strategies are enthusiastically discussed among the esteemed panel members. This truly unique series is designed for fellows, residents, and eye care specialists who recently entered practice and are involved in the management of patients with vitreoretinal disorders.
VBS Fellows' Foray 2025: Retina’s Believe It or Not: Case-Based Examples and Real-World Treatment Strategies
Media formats available:
Details
Presenters
Target Audience
This certified continuing medical education activity is designed for residents, fellows, and early-career retina specialists involved in the care of patients with vitreoretinal disorders.
Grantor Statement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Utilize imaging techniques to enhance the identification of key anatomical and pathological features, and improve diagnostic accuracy and treatment planning
- Discuss the rationale behind choosing specific medical and/or surgical approaches to manage vitreoretinal conditions
- Formulate strategies to mitigate, promptly detect, and manage complications that may arise during vitreoretinal surgery
Accreditation and Credit Designation Statements
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Disclosure of Relevant Financial Relationships
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.Carl C. Awh, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Bausch + Lomb, Carl Zeiss Meditec, Genentech, and Ocular Therapeutix. Grant/Research Support: 4DMT, Adverum, Allergan, Apellis, Astellas, Aura Biosciences, Aviceda, Chengdu Kanghong Biotechnology, Cognition Therapeutics, Genentech, Ionis Pharmaceuticals, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Ocular Therapeutix, Oxurion NV, Regeneron, Regenxbio, and Stealth Biotherapeutics. Speaker’s Bureau: Genentech. Royalties: Bausch + Lomb, Carl Zeiss Meditec, and Harrow.
Sonny Caplash, MD, has had no financial relationship or affiliation with the ineligible companies.
Yewlin E. Chee, MD, has had no financial relationship or affiliation with the ineligible companies.
James P. Dossett, MD, has had no financial relationship or affiliation with the ineligible companies.
Jacob Grodsky, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences.
Muhammad Hassan, MD, has had no financial relationship or affiliation with the ineligible companies.
Eric E. Jung, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: EyePoint Pharmaceuticals and Physician’s Education Resource.
Paulina Ramirez Neria, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen. Speaker’s Bureau: Amgen.
Anton Orlin, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Apellis Pharmaceuticals, Genentech, and Regeneron.
Carolyn K. Pan, MD, has had no financial relationship or affiliation with the ineligible companies.
Aleksandra Rachitskaya, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie/Allergan, Alcon, Apellis Pharmaceuticals, Boehringer Ingelheim, EyePoint Pharmaceuticals, Iveric Bio, Ocular Therapeutix, Regeneron, Roche/Genentech, and Samsara Therapeutics. Speaker's Bureau: Apellis Pharmaceuticals, Genentech, Iveric Bio, and Regeneron.
Joaquín Ignacio Romano, MD, has had no financial relationship or affiliation with the ineligible companies.
Mark P. Seraly, MD, has had no financial relationship or affiliation with the ineligible companies.
Saumya M. Shah, MD, has had no financial relationship or affiliation with the ineligible companies.
Camila Ventura, MD, PhD, has had no financial relationships or affiliations with ineligible companies.
Edward H. Wood, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan, Apellis Pharmaceuticals, Genentech, Johnson & Johnson Vision, Ocular Therapeutix, Opthea, Regenxbio, and Siloam Vision. Grant/Research Support: Coherus Biosciences, EyeBio, Henlius, Opthea, Regeneron, Regenxbio, Unity Biotechnology, and Valo Health. Speaker's Bureau: Astellas and Evolve. Common Stock: Quadrant Eye. Patent: Vortex.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Yewlin E. Chee, MD
Host
Anton Orlin, MD
Host
Aleksandra Rachitskaya, MD
Host
Camila Ventura MD, PhD
Host
Edward H. Wood, MD
Host
Carl C. Awh, MD, FASRS
Guest
Carolyn K. Pan, MD
Guest
Paulina Ramírez Neria, MD
Guest
Sonny Caplash, MD
Guest
James P. Dossett, MD
Guest
Jacob Grodsky, MD
Guest
Muhammad Hassan, MD
Guest
Eric E. Jung, MD
Guest
Joaquín Ignacio Romano, MD
Guest
Mark P. Seraly, MD
Guest
Saumya M. Shah, MD
Guest
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
Justis P. Ehlers, MD, FASRS
Roger A. Goldberg, MD, MBA
Jennifer, I. Lim, MD, FASRS, FARVO
Ehsan Rahimy, MD
- COPE ACCREDITED CE OFFERED
Charting GA Progression: From Early Signs to Treatment Strategies
1.00 creditRoger A. Goldberg, MD, MBA
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
